<DOC>
	<DOCNO>NCT00593697</DOCNO>
	<brief_summary>The purpose study compare disease-free survival ( DFS ) woman treat concomitant trastuzumab plus docetaxel follow FEC woman treat regimen follow single-agent trastuzumab complete one year trastuzumab administration adjuvant treatment early HER2-positive breast cancer .</brief_summary>
	<brief_title>The Synergism Or Long Duration ( SOLD ) Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Patient provide write informed consent prior studyspecific screening procedure , understand right withdraw study time , without prejudice . 2 . Woman &gt; 18 year age . 3 . Histologically confirm invasive breast cancer . 4 . HER2positive breast cancer ( preferably assess CISH FISH ; available immunohistochemistry 3+ ) 5 . A high risk breast cancer recurrence one following : Pathological N0 long invasive tumor diameter &gt; 5 mm Histologically confirm regional node positive disease ( pN+ ; nodal isolated tumor cells/cell cluster &lt; 0.2 mm diameter ( ITP ) count metastasis ) 1 . Presence distant metastasis . 2 . Inflammatory breast cancer . 3. pT1bN0M0 ( i.e . long tumor diameter 6 10 mm , nodenegative ) histological grade 1 . 4 . Clinically significant ( i.e . active ) cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 12 month . 5 . Left ventricular ejection fraction le 50 % ( institutional normal reference range ) assess echocardiography isotope cardiography . 6 . ER , PgR HER2 status ( via situ hybridization immunohistochemistry ) determine . 7 . Primary systemic cancer therapy ( neoadjuvant chemotherapy endocrine therapy ) administer prior breast surgery . 8 . The WHO performance status &gt; 1 . 9 . Pregnant lactating woman . 10 . Women childbearing potential unless use reliable appropriate contraceptive method . Women must amenorrheic least 12 month prior study entry consider postmenopausal childbearing potential . Women childbearing potential ( menstruate within 12 month study entry ) , hysterectomy age &lt; 55 , must negative pregnancy test baseline . 11 . More 12 week breast surgery date randomization . 12 . Organ allografts immunosuppressive therapy require . 13 . Major surgery ( except breast surgery ) within 4 week prior study treatment start , lack complete recovery effect major surgery . 14 . Participation investigational drug study within 4 week precede treatment start . 15 . Patients history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant preclude study participation . 16 . History another malignancy within last five year except cure basal cell carcinoma skin carcinoma situ uterine cervix . 17 . One following : Blood hemoglobin &lt; 10.0 g/dL , neutrophils &lt; 1.5 x 109/L , platelet count &lt; 120 x 109/L Serum/plasma creatinine &gt; 1.5 x Upper Limit Normal ( ULN ) Serum/plasma bilirubin &gt; ULN Serum/plasma ALT and/or AST &gt; 1.5 x ULN Serum/plasma alkaline phosphatase &gt; 2.5 x ULN 18 . Serious uncontrolled infection serious uncontrolled concomitant disease . 19 . Unwilling unable comply protocol duration study . 20 . History hypersensitivity investigational product drug similar chemical structure . 21 . Preexisting motor sensory neurotoxicity severity â‰¥ grade 2 CTCAE version 3 , unless related mechanical etiology .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>chemotherapy</keyword>
</DOC>